Patent ID: 8758757
Filing Date: 2014-06-24
Classification: A61K,A61P,C07K

Abstract:
1. A method for inhibiting, in a patient having systemic lupus erythematosus, Crohn's disease, or ulcerative colitis, the binding of type I interferon to IFN alpha receptor-1 on a cell expressing IFN alpha receptor-1, comprising contacting the cell with a humanized antibody or humanized antibody fragment that specifically binds IFN alpha receptor-1, wherein said humanized antibody or humanized antibody fragment comprises: a heavy chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; a light chain variable region comprising the complementarity determining region amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO6; and heavy chain and light chain variable domain consensus framework regions, wherein the heavy chain variable domain consensus framework regions comprise at least one variable region residue, or combination of residues, chosen from: an alanine at residue 24H; a methionine or an alanine at residue 29H; an isoleucine at residue 37H and a threonine at residue 40H; a proline at residue 40H; a lysine at residue 71H; a leucine at 78H, wherein the variable region residue is identified utilizing the Kabat numbering system; and the light chain variable domain consensus framework regions comprise at least one variable region residue chosen from: an alanine at residue 19L; a leucine at residue 37L; an alanine at residue 46L; an isoleucine at residue 58L; an aspartic acid at residue 70L; and a threonine at residue 83L, wherein the variable region residue is identified utilizing the Kabat numbering system.